|
5.6.10 ESMO - Vessie
|
|
|
|
|
|
5.6.11 ESMO- Rein
|
|
|
|
|
|
|
|
|
5.6.13 ESMO - Prostate
|
|
|
|
|
|
|
|
5.6.14 ESMO - Ovaire
|
|
|
|
|
5.6.17 ESMO - Foie
|
|
|
|
5.6.19 ESMO - Médecine personnalisée
|
|
|
|
|
|
|
|
|
Roche takes on Loxo, Bayer in gene-defined cancer class [Reuters]
|
|
|
|
|
|
Loxo’s
larotrectinib pill, co-developed with Bayer, was last year shown to
shrink tumors in 75 percent of patients with the NTRK fusion gene
anomaly, occurring in the lung, pancreas, or more than a dozen other
organs. On Sunday, the response rate to larotrectinib within an enlarged
group of 122 trial participants - up from 55 initially and now spanning
24 tumor types - was shown to be 81 percent.
|
|
|
|
|
|
|
5.6.2 ESMO - Divers
|
|
|
|
|
|
|
|
5.6.3 ESMO - Trastuzumab
|
|
|
|
5.6.4 ESMO - Poumon
|
|
|
|
|
|
|
|
|
5.6.4.1 ESMO - Poumon (atezolizumab)
|
|
|
|
|
|
|
5.6.4.2 ESMO - Poumon (crizotinib, ...)
|
|
|
|
|
|
5.6.5 ESMO - Mélanome & Peau
|
|
|
|
|
|
5.6.6.1 ESMO - Sein (triple négatif)
|
|
|
|
|
|
|
|
|
5.6.6.2 ESMO - Sein (alpelisib)
|
|
|
|
|
|
|
5.6.6.3 ESMO - Sein (palbociclib)
|
|
|
|
|
5.6.7 ESMO - Immunothérapies
|
|
|
|
|
5.6.8 ESMO - Côlon-rectum
|
|
|
|
|
|